Assembly Biosciences Q3 revenue falls 72%, misses estimates

Assembly Biosciences reported third-quarter 2026 revenue of about $3 million, down from $10.8 million a year earlier and below analyst expectations, while its loss per share of $0.93 was also worse than forecast. The revenue decline was primarily attributed to an adjustment to the transaction price of its Gilead HPI license, partly offset by increased work under the collaboration. The company began a Phase 2 trial of ABI-6250 for chronic hepatitis delta and said it expects to start another liver-disease Phase 2 study in early 2027. It also exercised an option to share 40% of U.S. development costs and profits for Gilead’s herpes simplex virus helicase-primase inhibitor program. Assembly received a $75 million Gilead collaboration extension fee and projected its cash runway into 2029.